

Release of Enight v2.3 expands commercial platform capabilities to 12 applications and includes Sectra integration

- **Upgraded SaaS-based Enight v2.3 released, expanding Enight from 8 to 12 commercial applications,** broadening the platform across migration, operational analytics and clinical workflow use cases (*see table below*)
- **Expanded applications are available to existing Enight customers as additional subscriptions,** creating an opportunity to deliver additional value across the installed base and grow annualised recurring revenue ('ARR')
- **Integrated Migration & Archive Standardisation enables Enight to be deployed as imaging archives are moved,** creating a direct pathway from Enlitic's established migration engagements into recurring software use cases
- **Introduction of the Enight integration into Sectra software systems,** the second major OEM environment alongside Intelera where Enight can be integrated
- **Sectra is a leading global player in the enterprise medical imaging market, managing over 170 million annual imaging exams and serving health systems across more than 2,500 sites worldwide**
- **A third major OEM integration is included in the release, subject to customer validation testing,** which is currently completing final validation, with details expected before the end of 2026

Please view the announcement here on our website: <https://enlitic.com/link/PwEX2e>

6 October 2026: Enlitic, Inc. (ASX: ENL) ("Enlitic" or the "Company") is pleased to announce the release of Enight v2.3, the latest version of its AI-driven SaaS-based medical imaging data standardisation and governance platform. The release adds four new commercial capabilities and introduces integration with Sectra software systems, a leading provider to health systems worldwide, expanding both what Enlitic can sell to each customer and the imaging environments it can sell into.

Enlitic's growth strategy is built on a land and expand model. Near-term migration projects win the customer and generate near-term revenue. Enight is then embedded within the customer's environment, providing the opportunity for a recurring subscription, with further capabilities and applications able to be added over time.

Enight v2.3 strengthens both sides of that commercial model. The new migration and archive standardisation integration API allows Enight to be deployed from the start of a migration project, creating a more direct pathway from project-based migration work into potential recurring revenue. The additional workflow and analytics capability gives each Enight customer more to adopt on the same standardised data layer, without new infrastructure.

The integration with Sectra PACS greatly expands the addressable market for Enight by enabling healthcare organisations operating Sectra's enterprise imaging environment to access Enlitic's AI-driven standardisation for data management, and migration capabilities without replacing their existing core imaging infrastructure.

Sectra is a leading global provider of medical imaging and enterprise healthcare IT solutions, with its systems managing more than 170 million imaging examinations annually, giving Enlitic access to a broad and established customer base across health systems worldwide.

With Ensign now interoperable with both Sectra PACS and Intelrad, Enlitic can deploy a repeatable integration framework across two major medical imaging OEM ecosystems, reducing implementation friction and supporting faster, more scalable adoption of Ensign by healthcare providers worldwide. This expanded interoperability strengthens Enlitic's ability to reach healthcare organisations through the imaging platforms they already use, accelerating Ensign's market penetration while supporting a more efficient and scalable go-to-market model.

The table shows the expansion of Ensign's commercial capability applications and OEM integrations since its launch.

Release	2023	2024	2025	Feb 2026	Sep 2026
Ensign version	v1.0+	v2.0+	v2.1+	v2.2	v2.3
Commercial Capability Applications					
ENDEX Standardisation	✓	✓	✓	✓	✓
Standardised data for Hanging Protocols		✓	✓	✓	✓
ENCOG De-identification			✓	✓	✓
Automatic Selection of Dictation Report Templates			✓	✓	✓
Data Dashboarding			✓	✓	✓
Metadata configuration and tooling for Data Analysis				✓	✓
Standardised data for Billing Systems				✓	✓
Creation and Storage of a Structured Metadata Index				✓	✓
Productivity & Operational Analytics					✓
Mass Archive Standardisation					✓
Integrated Migration & Archive Standardisation					✓
Standardised data for Automated Case Allocation					✓
RadLex & SNOMED CT Code Output					
Procedure Code Inferencing					
Billing/Coding Optimisation					
Data Management Analytics & Workflows for Research					
Bulk De-identification for Research					
Major OEM Integrations					
Intelrad				✓	✓
Sectra					✓

✓ Available in release ■ Future functionality planned for 2027

Future functionality is indicative only and remains subject to development, validation and commercial prioritisation.

Ensign v2.3 Additional Applications

Productivity & Operational Analytics gives customers visibility of standardisation throughput and results, laying the foundation for broader data quality measurement and operational analysis and creating an additional analytics use case within the same Ensign deployment.

Mass Archive Standardisation applies Enight standardisation across a customer's historical imaging archive at scale. The University of Michigan Health-Sparrow project announced on 28 September 2026 incorporates Enight standardisation across the historical imaging archive, with ~10.6 million radiology and cardiology imaging studies in scope.

Integrated Migration & Archive Standardisation standardises imaging data as it is migrated to a new environment, so customers establish a consistent data foundation as part of the migration rather than carrying existing inconsistencies into a new system. This allows Enight to be introduced as part of the migration engagement itself rather than relying on a separate post-migration deployment.

Standardised data for Automated Case Allocation uses the standardised imaging data to allow automatic directing of each study to the most appropriate radiologist, extending Enight data standardisation to support day-to-day operational workflow automation.

The v2.3 release also includes a new Export API that makes standardised study and series data available for reporting, analysis and ingestion into other systems, improved AI models for X-ray and de-identification and faster incremental processing with transferable configuration profiles that simplify deployment and upgrades.

The new version of Enight will enable integration with customers of a 3rd OEM subject to customer validation testing. Enight v2.3 also includes a third major OEM integration, beyond Intelrad and Sectra, subject to customer validation testing. The Company expects to announce details of successful validation before the end of 2026. Integrations with imaging platforms that hospitals already own create additional deployment pathways, reduce implementation complexity and shorten the time from contract to revenue.

Looking ahead, five further commercial applications are planned for 2027, expected to extend Enight into support for RadLex and SNOMED CT code output, procedure code inferencing, billing and coding optimisation, and research data management and bulk de-identification. These target revenue cycle and research use cases where standardised imaging data is a prerequisite.

Enlitic CEO Michael Sistenich said: *"Enight v2.3 expands both what we can sell and where we can deploy it. Moving from 8 to 12 commercial applications means customers can apply the same governed data foundation to more workflows, while the new migration and OEM capabilities give us additional points of entry into large health systems."*

With Enight now able to be integrated across customer sites that operate Intelrad and Sectra software systems, we now have a much larger foundation from which to grow ARR from Enight integrations. It is consistent with our robust commercial model: land through migrations and OEM channels, then expand the relationship through additional recurring software use cases over time. We expect to report a successful validation of a third OEM integration before the end of 2026, multiple Enight go lives and additional high value migration contracts. Enlitic has excellent commercial momentum across multiple markets."

This announcement was authorised for release by the Board of Enlitic, Inc.

- ENDS -

About Enlitic

Enlitic is a software company that uses artificial intelligence to develop software products that manage medical imaging data in radiology (such as MRI, CT scans, Xray and ultrasound images) and licences such products to healthcare providers. Enlitic's products (including its current product offering and product suite under development) seek to standardise, protect, integrate, and analyse data to create the foundation of a real-world evidence platform that can improve clinical workflows, increase efficiencies, and expand capacity. Read more at enlitic.com.

Enlitic's CDIs are traded on ASX in reliance on the safe harbour provisions of Regulation S under the US Securities Act of 1933 as amended, and in accordance with the procedures established pursuant to the provisions of a no action letter dated 7 January 2000 given to ASX by the staff at the US Securities and Exchange Commission. The relief was given subject to certain procedures and conditions described in the no action letter. One of the conditions is that the issuer provides notification of the Regulation S status of its securities in communications such as this announcement.

Forward-looking statements

Certain statements made during or in connection with this announcement contain or comprise certain forward-looking statements regarding the Company, its projected cash flow, financial performance, its customer contracts and customer pipeline and product development. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, such expectations are only predictions and are subject to inherent risks and uncertainties which could cause actual values, results, performance or achievements to differ materially from those expressed, implied or projected in any forward-looking statements and no assurance can be given that such expectations will prove to have been correct.

Accordingly, results could differ materially from those set out in the forward-looking statements as a result of, among other factors, changes in economic and market conditions, delays or changes in product development and realisation of customer pipeline, changes in demand, success of business and operating initiatives, changes in the regulatory environment and other government actions, fluctuations in exchange rates and business and operational risk management.

To the maximum extent permitted by law, each of the Company, its officers, employees and advisers expressly disclaim any responsibility for the accuracy or completeness of the material contained in these forward-looking statements and excludes all liability whatsoever (including in negligence) for any loss or damage which may be suffered by any person as a consequence of any information in forward-looking statements or any error or omission. The Company undertakes no obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events other than required by the applicable laws, including the ASX Listing Rules. Accordingly, you should not place undue reliance on any forward-looking statement. Read more at enlitic.com

About Sectra

Sectra is a publicly traded Swedish medical technology company. With over 30 years of innovation, Sectra manages 170 million annual imaging exams and is a leading provider to health systems worldwide. Imaging modules for radiology, cardiology, pathology, orthopaedics, ophthalmology, and genomics, as well as a robust VNA and an optimized workflow engine, form an integrated enterprise diagnostic solution designed to support both human driven and AI driven clinical workflows. In 2026, Sectra won 7 Best in KLAS awards for the highest customer satisfaction. Visit <https://sectra.com/>

Further information:

Ben Jarvis
Six Degrees Investor Relations
Ph: 0413 150 448
Ben.jarvis@sdir.com.au